BioCurity Pharmaceuticals Inc.

Because we believe that fighting cancer is hard enough!

BioCurity Pharmaceuticals Inc.

Because we believe that fighting cancer is hard enough!

Jupiter, FL
Biotechnology
BioCurity is a biopharmaceutical company developing drugs to transform radiation therapy. Our mission is to prevent certain side effects of radiation therapy for cancer patients. The side effects range from burns to the skin for breast cancer patients to pneumonia for lung cancer patients. Damage to healthy tissue of cancer patients undergoing radiation therapy is a direct cause of these side effects. The proposed drugs under development are from BioCurity’s patented technology and have been preclinically tested for multiple cancers including breast, lung, head and neck, prostate and colorectal cancer. Consistent with our preclinical studies we intend to mitigate side effects of radiation therapy without impairing the effectiveness of radiation treatment.

$198,203

raised
188
Investors
$36.3M
Valuation
$4.25
Price per Share
$510.00
Min. Investment
Preferred
Shares Offered
Equity
Offering Type
$600K
Offering Max
17
Days Left

$198,203

raised
188
Investors
$36.3M
Valuation
$4.25
Price per Share
$510.00
Min. Investment
Preferred
Shares Offered
Equity
Offering Type
$600K
Offering Max
17
Days Left

Rewards

Get rewarded for investing more into BioCurity Pharmaceuticals Inc.:

$510+
Investment
StartEngine Owner’s Bonus
This offering is eligible for the StartEngine Owner’s 10% Bonus program. For details on this program, please see the Offering Summary section below.

Reasons to Invest

Our proposed drugs are intended to provide cost effective protection for millions of cancer patients undergoing radiation therapy every year from the side effects of radiation therapy
Seven issued US patents with fully paid license for its technology in the US as well as international patents owned by the Company for our technology when patients are undergoing radiation combined with chemotherapy
BioCurity management is focused on meeting development milestones of the proposed drug (including a growing IP portfolio) and thereby increasing the valuation of BioCurity for investors with funds that are raised

Approximately 150 investors participated in BioCurity’s prior Crowdfunding offering. With a minimum investment of $510 you can become part of the solution to prevent radiation side effects. Discussions and due diligence are ongoing with quality healthcare strategic partners and institutional funds.

Collectively, we can make progress in developing drugs to transform radiation therapy.

Learn more about BioCurity

"Because we believe that fighting cancer is hard enough"

Radiation therapy is a common cancer treatment that can have serious side effects

Did you know that radiation therapy, just like chemotherapy, can cause harmful and medically detrimental side effects for patients with cancer?


Drugs that reduce side effects of chemotherapy have been developed by major pharmaceutical companies such as Amgen and GlaxoSmithKline.   A supportive care drug to mitigate the side effects caused by radiation therapy for cancer patients is long overdue. It could transform essential radiation treatment for cancer patients into a more tolerable therapy with fewer long-term negative consequences.


Complications and side effects of radiation therapy we seek to reduce include :

1. Ryan, Julie. “Ionizing Radiation: The Good, the Bad, and the Ugly”. J Invest Dermatol. 132 (2012): 985-993

2. Bray, Fleta, et al. “Acute and Chronic Cutaneous Reactions to Ionizing Radiation Therapy.” Dermatol Ther. 6 (2016): 185-206

3. Radvansky, Lauren, et al. “Prevention and Management of Radiation-Induced Dermatitis, Mucositis and Xerostomia.” Am J Health Syst Pharm. 12 (2013): 1025-1032

4. Peach, Matthew, et al. “Systematic Review of the Relationship between Acute and Late Gastrointestinal Toxicity after Radiotherapy for Prostate Cancer.” Prostate Cancer. 15 (2015): 1-11

BioCurity is looking to move forward in developing its proposed drugs and positively impact the cancer treatment process for millions of patients worldwide.


Imagine…if cancer patients no longer had to worry about whether or not they were going to suffer from their radiation treatment

There is an unmet patient need to prevent or mitigate the side effects of life-saving radiation therapy

The lack of adequate treatment options available to prevent or mitigate the damage to normal tissue causes an unmet global need for millions of cancer patients. In 2018, $3 Billion in the United States alone was billed by hospitals for in-patient medical care costs to treat medical complications caused by radiation therapy - and this does not include the emotional costs endured by the cancer patients and their families. With topical tissue damage, scarring of breasts, or disfigurement of the head and neck area, cancer radiation leaves patients with permanent damage. 


We believe the use of BioCurity’s technology would save billions of dollars a year spent for inpatient treatment of radiation therapy side effects by eliminating the need for hospital stays globally.


Preclinical studies completed and third-party experts see promise

Radiation treatment for cancer patients causes damage to cell DNA and normal cells die. This death of normal cell causes the side effects. The driver in the cell death is the free radicals that are created by the radiation.

How it works

Eliminating Free radicals

BioCurity’s proprietary technology is intended to eliminate these free radicals, protecting the skin and healthy internal tissues from unwanted DNA damage and the ensuing side effects- without interfering with the treatment of cancer cells. Our first proposed drug is a topical for radiation dermatitis and with the support from a biotech venture or as part of a joint venture with a pharma company, we believe we would meet our goal to develop our proposed IV drug for the prevention of internal tissue radiation damage.

Source, Source, Source, Source, SourceSource

Why our drug is needed now more than ever

Healthcare services globally are in a limited supply and that has been demonstrated in today’s fight against the COVID pandemic. There is no better time to develop drugs that can reduce patient services including in-hospital stays and save billions of healthcare dollars annually. Cancer treatments and radiation therapy are not elective procedures and continue irrespective of the other demands on hospitals and healthcare services.

Every patient with cancer undergoing radiation therapy

Globally, approximately 6 million out of the approximate 18 million newly diagnosed cancer patients receive radiation therapy annually and 1 million of them live in the United States. BioCurity’s proposed drugs have the potential to significantly reduce radiation side effects for a plurality of these patients. Cancer survivors treated with radiation therapy for pain management, recurring or secondary cancers are also projected to benefit from our drug products.

The global radiation therapy market was valued at $5 Billion in the year 2019 and is expected to reach $10 Billion by year 2025 with the Asia-Pacific region the fastest growing regional market. The global radiation therapy market forecasts are primarily supported by the increasing incidence of cancer and related mortality globally and a higher demand and increasing adoption of radiation therapy for the treatment of various types of cancers.

Source

The first target market we intend to test with our topical drug is breast cancer patients. It is expected to provide a material decrease in government and insurance funds required to treat skin damage of burns, scars, and blisters:


  • Breast cancer is leading cancer in the United States for women, and it is estimated that 1 in 8 women in the United States will develop breast cancer over their lifetime.
  • Radiation treatment for breast cancer can be used after lumpectomy, after mastectomy, for pain management, for managing metastatic breast cancer and for treating locally advanced breast cancer.
  • Some form of skin damage has been referenced in the scientific literature to inflict nearly all women with breast cancer who are receiving radiation therapy.
  • The short term and long term skin damage associated with radiation therapy for breast cancer patients include localized burning and blisters that can often be permanent, open wounds, extreme swelling and tenderness of the breast and surrounding lymph nodes, and permanent scars.


Increasing the attractiveness to capital markets

With a fully paid license for its technology that is freely transferable and growing International patent portfolio, BioCurity is well situated for collaborative transactions with pharmaceutical strategic groups. We work with a lean team of professionals compared to many Biotech companies. Consultants are utilized to reduce the burn rate during this growth process. We anticipate as the market in biotech typically demonstrates, valuation increases as the product progresses through clinical development as the safety and efficacy data would have significant appeal to other pharmaceutical companies.  Favorable exit strategies for biotech companies include proceeding with clinical development up through a demonstration of clinical efficacy and then licensing the product or soliciting an acquisition.

Management has made efforts to structure the company with multiple exit strategies along the path of growth, to enable it to consider opportunities at any point along its growth curve.  BioCurity has audited financial statements to be transaction ready with a full corporate diligence room.

Striving to be an effective and FDA approved drug for the prevention of radiation dermatitis

BioCurity and its drug development and clinical consultants, believe its proposed topical drug is reasonable to manufacture, and if proven safe and effective can be marketed efficiently, and may be reimbursable as a supportive care product. The currently available treatments used to manage side effects from radiation have limited effectiveness and a large number of potential cancer patients represent a significant and global unmet need and tremendous value proposition for BioCurity’s proposed topical drug and other potential drugs such as the IV formulation for the protection of internal tissues.

IAEA Report 2017, Radiotherapy in Cancer Care, Facing the Global Challenge.

Improving the quality of life for cancer patients and survivors undergoing radiation therapy worldwide

Over the next three years, given adequate funding, we will be working to clinically develop our topical product for breast cancer patients. We intend to build out a management team, engage in-house consultants from the drug industry and execute the product development activities required to submit the Investigational New Drug Application for a breast cancer product.


While our immediate focus is developing a new investigational topical product for breast cancer radiation therapy, we have greater aspirations. With the establishment of efficacy for breast cancer then additional clinical trials with our topical product for other cancers could begin. Eventually, with a joint venture with a pharma company or support from a biotech venture fund, we aim to develop an IV formulation of our product designed to protect the internal tissue from radiation.

A strong management team and roster of advisors

BioCurity’s team is balanced by decades of experience in science, international business operations, and legal/banking experience.


Dr. Cheryl Baker Ph.D., the scientific founder, performed the preclinical development and testing alongside radiation oncologists, medical oncologists, and others in the medical community. She has published more than 45 peer-reviewed manuscripts, book chapters, and articles. 


Chairman of the Board, Sam Merchant, brings expertise in structuring and negotiating transactions globally in Biotechnology, Pharmaceutical R&D in the production, manufacturing, and distribution of products provides value-added for BioCurity’s overall clinical development goals. 


Executive board member Nancy Cass, Esq, uses her depth of knowledge in transactional and securities law to make certain BioCurity is transaction-ready and the due diligence and corporate governance is properly performed and managed. 


BioCurity is also guided by a group of expert third-party advisors with substantial experience in all phases of drug development and the biotech industry - they are our very dedicated Consultants and Advisors - MDs, PhDs, MBAs, with decades of Biotech experience.

Join us in transforming radiation therapy for cancer patients

BioCurity is sharing its story and reaching the non-accredited investors who can now become a part of BioCurity’s investment family. With adequate funding, we can continue to develop BioCurity’s drugs and meet the demand for a product that can transform the radiation therapy experience by limiting radiation therapy side effects. 


There is a pent-up demand for a supportive care product to transform and improve outcomes for cancer patients undergoing radiation therapy by reducing and preventing side effects. BioCurity’s goal is to have available its product to support all cancer patients undergoing radiation therapy and develop a drug to  improve the quality of life as a cancer patient and cancer survivor.  

Offering Summary


Company

:

BioCurity Pharmaceuticals Inc.

Corporate Address

:

110 Front Street, Suite 300, Jupiter, FL 33477

Offering Minimum

:

$9,996.00

Offering Maximum

:

$599,998.00

Minimum Investment Amount

(per investor)

:

$510.00











Terms


Offering Type

:

Equity

Security Name

:

Series 2 CF Convertible Preferred Stock

Minimum Number of Shares Offered

:

2,352

Maximum Number of Shares Offered

:

141,176

Price per Share

:

$4.25

Pre-Money Valuation

:

$36,320,126.00











Perks:

*Maximum Number of Shares Offered subject to adjustment for bonus shares. See Bonus info below

The 10% Bonus for StartEngine Shareholders

BioCurity Pharmaceuticals Inc. will offer 10% additional bonus shares for all investments that are committed by StartEngine Crowdfunding Inc. shareholders who invested over $1,000 or made at least two investments in StartEngine's own offerings.

This means eligible StartEngine shareholders will receive a 10% bonus for any shares they purchase in this offering. For example, if you buy 100 shares of Series 2 CF Convertible Preferred Stock at $4.25 / share, you will receive 110 Series 2 CF Convertible Preferred Stock, meaning you'll own 110 shares for $425. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.

This 10% Bonus is only valid during the investors eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are cancelled or fail.

Investors will only receive a single bonus, which will be the highest bonus rate they are eligible for.

Irregular Use of Proceeds

The Company might incur Irregular Use of Proceeds that may include but are not limited to the following over $10,000: Salary payments made to one’s self, a friend or relative.

Show More
Most recent fiscal year-end:
Prior fiscal year-end:
Total Assets
$222,611.00 USD
$342,484.00 USD
Cash And Cash Equivalents
$62,215.00 USD
$167,281.00 USD
Accounts Receivable
$0.00 USD
$0.00 USD
Short Term Debt
$1,524,330.00 USD
$780,203.00 USD
Long Term Debt
$0.00 USD
$0.00 USD
Revenues And Sales
$0.00 USD
$0.00 USD
Costs Of Goods Sold
$0.00 USD
$0.00 USD
Taxes Paid
$0.00 USD
$0.00 USD
Net Income
-$2,191,060.00 USD
-$1,570,893.00 USD

Risks

A crowdfunding investment involves risk. You should not invest any funds in this offering unless you can afford to lose your entire investment. In making an investment decision, investors must rely on their own examination of the issuer and the terms of the offering, including the merits and risks involved. These securities have not been recommended or approved by any federal or state securities commission or regulatory authority. Furthermore, these authorities have not passed upon the accuracy or adequacy of this document. The U.S. Securities and Exchange Commission does not pass upon the merits of any securities offered or the terms of the offering, nor does it pass upon the accuracy or completeness of any offering document or literature. These securities are offered under an exemption from registration; however, the U.S. Securities and Exchange Commission has not made an independent determination that these securities are exempt from registration.


Updates

Notice of Funds Disbursement

11 days ago

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, BioCurity Pharmaceuticals Inc. has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in BioCurity Pharmaceuticals Inc. be on the lookout for an email that describes more about the disbursement process.


This campaign will continue to accept investments until its indicated closing date.


Thanks for funding the future.

-StartEngine

BioCurity Summary of Updates since January – March 2021

about 1 month ago


Summary of Updates since January – March 2021


  • CLINICAL TEAM SECURED - CSSi LifeSciences www.cssilifesciences.com has been retained by BioCurity as a full-service clinical development team with experience in bringing hundreds of drugs from discovery to commercialization. This is an economically efficient model for BioCurity and provides access to a deep bench of professionals.  Please go to the CSSi website and see the depth of their team led by Jim Sergi. With Jim’s leadership and experience in supportive care oncology projects management is pleased to have retained CSSi and what a positive way to start out the New Year. Watch for updates!


  • SCIENTIFIC AND MEDICAL ADVISORY BOARD LAUNCHED - After much research and discussions internally, the first two members of the BioCurity Scientific and Medical Advisory Board have joined the BioCurity team. We could not be more thrilled than to welcome Dr. Chirag Shah, MD of Cleveland Clinic and Dr. Mark Ratain, MD of University of Chicago. Each member of the Scientific and Medical Advisory Board provides their unique experience. Dr. Shah, as a radiation oncologist with a patient centric view of treatment and Dr. Ratain, whose recognition as a Phase 1 expert will balance well with the rest of the BioCurity team. 


  • PATENT - BioCurity received an issuance from the Hong Kong Patent Office for BioCurity's HK patent #1237267B entitled "Treatment of Cancer with a Combination of Radiation, Cerium Oxide Nanoparticles, and a Chemotherapeutic Agent." This Hong Kong patent covers the use of cerium oxide nanoparticles for the reduction of side effects caused by radiation therapy for lung and pancreatic cancer patients receiving a combination of therapeutically effective doses of radiation therapy and chemotherapy as part of their treatment regimen.


We thank all of you who have become shareholders in BioCurity. The journey is underway. Please share information about BioCurity’s Crowdfunding Campaign. www.startengine.com/biocurity

Be sure to follow us on LinkedIn and Facebook

Team BioCurity – www.biocurity.com

Notice of Funds Disbursement

about 1 month ago

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, BioCurity Pharmaceuticals Inc. has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in BioCurity Pharmaceuticals Inc. be on the lookout for an email that describes more about the disbursement process.


This campaign will continue to accept investments until its indicated closing date.


Thanks for funding the future.

-StartEngine

BioCurity Announces Issuance of Hong Kong Patent

about 2 months ago




BioCurity Pharmaceuticals Inc. ('BioCurity') Announces Issuance of Hong Kong Patent for Reduction of Side Effects Caused by Radiation Therapy Combined with Chemotherapy 

 JUPITER, Fla., - BioCurity, a private preclinical biotech company with a mission to prevent radiation therapy's side effects for cancer patients and survivors, received an issuance from the Hong Kong Patent Office for BioCurity's HK patent #1237267B entitled "Treatment of Cancer with a Combination of Radiation, Cerium Oxide Nanoparticles, and a Chemotherapeutic Agent." This Hong Kong patent covers the use of cerium oxide nanoparticles for the reduction of side effects caused by radiation therapy for lung and pancreatic cancer patients receiving a combination of therapeutically effective doses of radiation therapy and chemotherapy as part of their treatment regimen. BioCurity exclusively owns its international patents, which currently exist in China, Japan, Europe, and Hong Kong.

 

About BioCurity Pharmaceuticals Inc. 

BioCurity's proprietary technology is designed to protect normal cells from radiation damage without impacting the effectiveness of radiation treatment. Globally, approximately 6 million of the 18 million annually diagnosed new cancer patients receive radiation. The lack of a drug to protect cancer patients' internal tissues and skin from the short and long-term side effects of radiation therapy is a global unmet patient need. Invest in BioCurity through its Regulation Crowdfunding Campaign to support its drug development.  Visit BioCurity's website and follow them on LinkedIn and Facebook.

 

This news release contains forward-looking statements, including those relating to the product development of BioCurity Pharmaceuticals Inc. (the "Company" or "BioCurity"), clinical and regulatory timelines, market opportunity and other statements that are predictive in nature, or that depend upon or refer to future events or conditions. Forward-looking statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors, including the potential impact of the recent COVID-19 pandemic and the potential impact of sustained social distancing efforts, on our operations, clinical development plans and timelines, which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this news release. BioCurity's lead product candidate is in preclinical development and is not for sale or use. This news release is not an offer to buy any securities of the Company.

 

Notice of Material Change in Offering

about 2 months ago

[The following is an automated notice from the StartEngine team].

Hello! Recently, a change was made to the BioCurity Pharmaceuticals Inc. offering. Here's an excerpt describing the specifics of the change:


BioCurity Pharmaceuticals Inc. extended the length of their campaign.


When live offerings undergo changes like these on StartEngine, the SEC requires that certain investments be reconfirmed. If your investment requires reconfirmation, you will be contacted by StartEngine via email with further instructions.

Notice of Funds Disbursement

about 2 months ago

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, BioCurity Pharmaceuticals Inc. has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in BioCurity Pharmaceuticals Inc. be on the lookout for an email that describes more about the disbursement process.


This campaign will continue to accept investments until its indicated closing date.


Thanks for funding the future.

-StartEngine

Notice of Funds Disbursement

3 months ago

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, BioCurity Pharmaceuticals Inc. has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in BioCurity Pharmaceuticals Inc. be on the lookout for an email that describes more about the disbursement process.


This campaign will continue to accept investments until its indicated closing date.


Thanks for funding the future.

-StartEngine

BioCurity Pharmaceuticals Inc. ('BioCurity') Announces Engagement with CSSi LifeSciences

3 months ago

JUPITER, Fla., January 22, 2021 -- BioCurity Pharmaceuticals Inc. (www.biocurity.com) is pleased to announce its engagement of CSSi LifeSciences (www.cssilifesciences.com) as lead clinical advisor for its supportive oncology care drug under development.  CSSi LifeSciences is a global, innovative contract research organization (CRO) and consulting group that specializes in advancing drugs and medical device technologies from discovery to commercialization. With global expertise, CSSi LifeSciences has been a key partner in the development of more than 500 drugs, biologics, medical devices, and in-vitro diagnostics.

BioCurity aims to positively transform the path to recovery for cancer patients undergoing radiation therapy by addressing a global unmet need. The company’s lead drug is cerium oxide nanoparticles that are designed to prevent or mitigate some of the side effects associated with radiation therapy. Preclinical animal studies have demonstrated the technology has the potential to significantly reduce radiation toxicity in newly diagnosed cancer patients undergoing radiation therapy, as well as cancer survivors who have returned for more treatment, which includes radiation therapy. More importantly, the drug is designed to be effective without the risk of interfering with the efficacy of the targeted radiation therapy dosage. The first target market which BioCurity intends to test using the company’s proposed topical product is breast cancer patients.

"BioCurity as a global leader in drug development using cerium oxide nanoparticles to mitigate the side effects associated with radiation therapy," said Dr. Cheryl Baker, PhD. Scientific Co-Founder of BioCurity. The short and long-term side effects from radiation therapy can impair a cancer patient's medical treatment plan and can leave cancer survivors with permanent adverse conditions. "There is an estimated 3-billion-dollar healthcare cost for in-patient treatment of medical side effects from radiation therapy in the United States annually. The unmet need is well documented," said Dr. Baker, PhD. The global cancer supportive care market is poised to reach approximately 22 billion dollars by 2026.

Mr. Sam Merchant, Chairman of the Board of BioCurity stated “BioCurity is enthusiastic about working with CSSi LifeSciences. The team assembled by Mr. Jim Sergi, Founder of CSSi LifeSciences has many achievements in drug development from early stage through commercialization. With CSSi LifeScience’s direct experience in supportive care oncology drugs, we believe CSSi LifeSciences is a first-rate team to lead a successful clinical execution of BioCurity drugs under development to protect cancer patients from radiation therapy side effects. Millions of cancer patients and cancer survivors every year all over the world undergo radiation therapy to treat their cancer. CSSi LifeSciences understands the current unmet need and commercialization opportunities of BioCurity’s oncology supportive care drug.”

“We are excited to have the opportunity to leverage our oncology experience and expertise to advance the commercial development of BioCurity’s lead drug compound for patients undergoing radiation therapy. BioCurity offers the potential to prevent the often devastating side effects associated with radiation therapy and to enhance the treatment outcomes for patients,” stated Mr. Jim Sergi, President, CSSi LifeSciences.

About BioCurity Pharmaceuticals Inc. 

BioCurity's proprietary technology is designed to protect normal cells from radiation damage without impacting the effectiveness of radiation treatment. Globally, approximately 6 million of the 18 million annually diagnosed new cancer patients receive radiation. The lack of a drug to protect cancer patients' internal tissues and skin from the short and long-term side effects of radiation therapy is a global unmet patient need. Invest in BioCurity through its Regulation Crowdfunding Campaign to support its drug development.  Visit BioCurity's website and follow them on LinkedIn and Facebook.

This news release contains forward-looking statements, including those relating to the product development of BioCurity Pharmaceuticals Inc. (the "Company" or "BioCurity"), clinical and regulatory timelines, market opportunity and other statements that are predictive in nature, or that depend upon or refer to future events or conditions. Forward-looking statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors, including the potential impact of the recent COVID-19 pandemic and the potential impact of sustained social distancing efforts, on our operations, clinical development plans and timelines, which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this news release. BioCurity's lead product candidate is in preclinical development and is not for sale or use. This news release is not an offer to buy any securities of the Company.

BioCurity's Proposed Products and Supportive Oncology Care

3 months ago

WHAT IS ONCOLOGY SUPPORTIVE CARE? 

“So, the idea of whole-person care is actually supported by the integration of palliative and symptom management into standard oncology care. Many of our therapies result in long-term toxicities that need continuous management and ongoing attention, especially now with so many survivors living with cancer as a chronic disease,” said board certified medical and palliative oncologist Dr. Jamie Von Roenn, MD, FASCO while serving as Vice President of Education, Science, and Professional Development of American Society of Clinical Oncology (ASCO) at the 2019 Supportive Care in Oncology Symposium: Advancing Palliative Research Across the Care Continuum, held in San Francisco.1

Supportive care interventions can prevent or minimize the adverse effects of cancer and its treatment, across all phases of cancer patient’s experience. According to the National Cancer Institute, supportive care is defined as “care given to improve the quality of life of patients who have a serious or life-threatening disease. The goal of supportive care is to prevent or treat as early as possible the symptoms of a disease, side effects caused by treatment of a disease, and psychological, social, and spiritual problems related to a disease or its treatment2

Benefits of Supportive Care include:3, 4

  • Alleviation of symptoms and complications of cancer
  • Prevention or reduction of treatment toxicities
  • Increased tolerance, and thus benefits, of active therapy
  • Easing of the emotional burden for patients and caregivers
  • Decreased longer term costs and usage of the health care system
  • Improved communication between patients and caregivers

WHAT DOES THE PROJECTED MARKET FUTURE LOOK LIKE FOR SUPPORTIVE ONCOLOGY CARE?

Cancer is a major economic expenditure for all developed countries and cancer costs are expected to continue to rise due to an aging population and improvements in survival, as well as trends in treatment patterns and costs of care following cancer diagnosis.5 Cancer treatment-induced toxicities may not only distress the patients, but can also lead to treatment cessation, which in turn increases patient mortality. As the number of people being diagnosed with cancer grows and access to effective treatment that allows patients to survive longer increases, demand for safe and effective cancer supportive care drugs are on the rise. “Supportive care makes excellent cancer care possible, the strapline for the Multinational Association of Supportive Care in Cancer (“MASCC”), has never before been more relevant, for all countries at different stages of the current pandemic, as increased stressors threaten the wellbeing of people with cancer, their caregivers and healthcare professionals.”6

The cancer supportive care product market consists of drugs intended to prevent or treat the symptoms of cancer, and reduce the side effects of cancer treatments, with an emphasis on improving overall quality of life. The global cancer supportive care market is poised to reach $23B by 2026 and is driven by the growing prevalence of cancer cases.7 Lung and breast cancer are the most prominent cancer types with the highest demand for supportive care drugs.7

HOW DOES BIOCURITY’S PROPOSED PRODUCTS UNDER DEVELOPMENT FIT INTO SUPPORTIVE ONOCLOGY CARE?

BioCurity’s oncology supportive care drugs under development are designed to prevent certain side effects of radiation therapy for cancer patients. Drugs that reduce side effects of chemotherapy have been developed by some major pharmaceutical companies. An oncology supportive care drug to mitigate the side effects caused by radiation therapy for cancer patients could transform essential radiation treatment for cancer patients into a more tolerable therapy with fewer long-term negative consequences. 

Cancer treatments and radiation therapy are not elective procedures and continue irrespective of the other demands on hospitals and healthcare services. Approximately $3B was billed by hospitals in the US alone in 2018 for in-patient medical care costs to treat medical complications caused by radiation therapy.8,9 These economics do not include outpatient treatment costs, or the emotional costs endured by the cancer patients and their families. 

BioCurity’s oncology supportive care drugs, if proven safe and effective can make difference and reduce demands on hospitals, staff and insurance providers. 

“What we have in the pipeline with BioCurity Pharmaceuticals may be a really significant addition to our toolbox,” says Clarence Brown, MD, Former President and CEO of MD Anderson Cancer Center Orlando (formerly affiliated with Orlando Health) and current Board Chairman of the University of Central Florida Lake Nona Medical Center. 

After one of BioCurity’s presentations at an investor conference held in Miami, Florida, an Oncologist from the audience stated ‘It [BioCurity’s proposed products] is a game changer.” 

 

1. “Supportive Care in Oncology Symposium Emphasized Caring for the Whole Patient From Diagnosis to End of Life.” The ASCO Post. www.ascopost.com. 25 January 2020. Web. 30 December 2020. 

2. “Supportive Care.” National Cancer Institute. www.cancer.gov. 2020. Web. 30 December 2020.

3. “What is Supportive Care?” Multinational Association of Supportive Care in Oncology. www.mascc.org. 2020. Web. 29 December 2020. 

4. “Cancer Supportive Care Needs.” Australian Government Cancer Australia. www.edcan.org.au. 2020. Web. 29 December 2020. 

5. Berman, Rachel et al. “Supportive Care: An Indispensable Component of Modern Oncology.” Clinical oncology (Royal College of Radiologists (Great Britain)), 2020 3: 781-788. 

6. Young, Annie et al. “Uncertainty upon uncertainty: supportive Care for Cancer and COVID-19.” Support Care Cancer, 2020 28:4001–4004. 

7. “Cancer Supportive Care Drugs Market Size, Share & Trends Analysis Report By Therapeutic Class (G-CSFs, Bisphosphonates, Antiemetics, Opioids, NSAIDs, ESAs), By Region, And 

Broad Use of Radiation Treatment - American Cancer Society Report

3 months ago

Given the broad use of radiation therapy in the treatment of cancer for cancer patients and cancer survivors, millions of cancer patients could be positively impacted if some radiation therapy side effects can be prevented or mitigated. 

 “One of the most common treatments is radiation also referred to as radiation therapy, radiotherapy, irradiation, and x-ray therapy. This therapy uses high doses of radiation to kill cancer cells and shrink tumors. More than half of patients with cancer undergo radiation therapy, either alone or in conjunction with other treatment(s).”

According to the American Cancer Society, the goals of this treatment are often one of the following:2

To cure or shrink early-stage cancer. Radiation can sometimes shrink the cancer or make it go away entirely. Sometimes, patients may receive chemotherapy or other anti-cancer drugs first. Other patients may undergo treatment before surgery to shrink the tumor—which would be referred to as neoadjuvant therapy—or they may receive radiation postoperatively to prevent the cancer from coming back—which would be referred to as adjuvant therapy.

To stop cancer from coming back somewhere else. There is a possibility of cancer spreading to other parts of the body, even if it doesn’t show up on imaging scans. Radiation may then be used as a cautionary treatment, to kill cancer cells that may have spread to an area of the body commonly associated with the spot of the primary cancer before they become tumors.

To treat symptoms caused by advanced cancer. It may also be used as part of palliative cancer treatment in patients whose cancer cannot be cured. In these cases, the goal is to shrink the tumors to help relieve some of their associated symptoms, in order to make the patient more comfortable.

To treat cancer that has returned. Patients with recurrent cancer may undergo this therapy to either treat the cancer or its symptoms. This depends on where the recurring cancer is, however. If it’s in an area of the body that previously underwent radiation treatment, repeating radiation may not be possible.

Help us make BioCurity’s drugs in development be successful by preventing and mitigating radiation side effects.  http://www.startengine.com/biocurity 

Because we believe that fighting cancer is hard enough…

Team BioCurity

Follow us on LinkedIn, Facebook and Website

 

1”How Radiation Therapy Is Used to Treat Cancer.” American Cancer Society. www.cancer.org. 19 December 2019. 

“BLOG: What Cancers Require Radiation?” DocWireNews. https://www.docwirenews.com/docwire-pick/what-cancers-require-radiation/ 2 December 2020. 

 

BioCurity speaks with Chief Radiation Therapist

3 months ago

WATCH: As BioCurity’s scientific founder Cheryl Baker, PhD speaks with Mr. Michael Brown, Chief Radiation Therapist at Orlando Health UF Health Cancer Center about the side effects of radiation therapy and the unmet need of BioCurity's oncology supportive care drugs under development. Side effects from radiation therapy affects millions of people annually, let’s make a difference… 

Because we believe that fighting cancer is hard enough. 

Team BioCurity

Follow us on LinkedIn and Facebook


Notice of Funds Disbursement

3 months ago

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, BioCurity Pharmaceuticals Inc. has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in BioCurity Pharmaceuticals Inc. be on the lookout for an email that describes more about the disbursement process.


This campaign will continue to accept investments until its indicated closing date.


Thanks for funding the future.

-StartEngine

BioCurity Wishes You and Yours a Happy New Year!

4 months ago

In the spirit of the holidays and nearing the end of 2020, BioCurity recognizes the sacrifices and gives thanks to the healthcare heroes, first responders, teachers and all front-line workers who continue to put the general public first in an effort to keep us safe and do their jobs well in spite of the challenges they face daily.

And many thanks to our investors!  What a challenging year this has been, and we appreciate your financial support to help us with our goal of developing supportive care oncology drugs to prevent and mitigate side effects of radiation therapy for cancer patients.   

Stay safe and enjoy the holidays. 

Team BioCurity

Follow us on LinkedIn and Facebook

Campaign for Crowdfunding Extended!

4 months ago

BioCurity has extended its Crowdfunding campaign. We are enthusiastic about keeping the investment opportunity open for those individuals who have not yet invested and for those who may want to re-invest.

Over the next 60 days we have plans to roll out updated information on our company through posts, updates to the CF page and videos. We plan to provide more information on oncology supportive care markets so please be watching for our social media posts.

We thank all of you who have joined the BioCurity investor family. Please share information about BioCurity so we can increase the knowledge about our company. 

Be sure to follow us on LinkedIn and Facebook as we continue to work virtually. 

Stay safe! 

Team BioCurity

Notice of Material Change in Offering

4 months ago

[The following is an automated notice from the StartEngine team].

Hello! Recently, a change was made to the BioCurity Pharmaceuticals Inc. offering. Here's an excerpt describing the specifics of the change:


BioCurity Pharmaceuticals, Inc. extended the length of their campaign.


When live offerings undergo changes like these on StartEngine, the SEC requires that certain investments be reconfirmed. If your investment requires reconfirmation, you will be contacted by StartEngine via email with further instructions.

BioCurity has been active working virtually!

4 months ago

The BioCurity team has been active working virtually to do its part to keep everyone safe. Our team presented or attended virtually multiple biotech conferences. During these conferences, BioCurity’s management presented and attended one-on-one partnering meetings with groups in Australia, Japan and throughout the United States.  Here are some details:

  • In July, the BioCurity team attended the Digital RESI Life Science Nation Partnering Program with over 450 investors and strategic partners in attendance 
  • In September, the BioCurity team presented at the BioPharma Oncology Virtual Partnering Conference co-hosted by Biotechnology Innovation Organization (BIO) and Inova and attended the OnRamp Healthcare Conference, the leading conference for the healthcare innovation, which brings together corporations, investors, startups, and members of the health care team. 
  • In October, the BioCurity team attended the Bio Investor Forum Digital 2020 conference which attracted 1,000 attendees from 32 countries and had the highest investor engagement since 2015
  • In November, the BioCurity team attended the Mass Bio Patient Advocate Summit 

BioCurity plans to continue to have a presence at several virtual biotech conferences scheduled in 2021, including Bio Partnering at JP Morgan in January, Bio Investor and CEO Conference in February, Venture Summit Virtual Connect in March and Bio International in June, with possibly others to consider.  

Thank you for your interest in BioCurity and our team continues to work virtually through the holidays. 

 

Notice of Funds Disbursement

4 months ago

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, BioCurity Pharmaceuticals Inc. has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in BioCurity Pharmaceuticals Inc. be on the lookout for an email that describes more about the disbursement process.


This campaign will continue to accept investments until its indicated closing date.


Thanks for funding the future.

-StartEngine

Notice of Funds Disbursement

5 months ago

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, BioCurity Pharmaceuticals Inc. has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in BioCurity Pharmaceuticals Inc. be on the lookout for an email that describes more about the disbursement process.


This campaign will continue to accept investments until its indicated closing date.


Thanks for funding the future.

-StartEngine

Notice of Material Change in Offering

6 months ago

[The following is an automated notice from the StartEngine team].

Hello! Recently, a change was made to the BioCurity Pharmaceuticals Inc. offering. Here's an excerpt describing the specifics of the change:


BioCurity Pharmaceuticals Inc extended their campaign 60 days.


When live offerings undergo changes like these on StartEngine, the SEC requires that certain investments be reconfirmed. If your investment requires reconfirmation, you will be contacted by StartEngine via email with further instructions.

Notice of Funds Disbursement

6 months ago

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, BioCurity Pharmaceuticals Inc. has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in BioCurity Pharmaceuticals Inc. be on the lookout for an email that describes more about the disbursement process.


This campaign will continue to accept investments until its indicated closing date.


Thanks for funding the future.

-StartEngine

BioCurity Press Release

6 months ago

BioCurity Pharmaceuticals Inc. ('BioCurity') Announces Issuance of European Patent for Reduction of Side Effects Caused by Radiation Therapy Combined with Chemotherapy 


JUPITER, Fla., October 2, 2020 /PRNewswire/ -- BioCurity, a private preclinical biotech company with a mission to prevent radiation therapy's side effects for cancer patients and survivors, received an issuance from the European Patent Office for BioCurity's EP patent #3169312 entitled "Treatment of Cancer with a Combination of Radiation, Cerium Oxide Nanoparticles, and a Chemotherapeutic Agent." This European patent covers the use of cerium oxide nanoparticles for the reduction of side effects caused by radiation therapy for lung and pancreatic cancer patients receiving a combination of therapeutically effective doses of radiation therapy and chemotherapy as part of their treatment regimen. BioCurity exclusively owns its international patents, which currently exist in China, Russia*, Japan*, and Europe.


"BioCurity is focused on expanding its patent portfolio and has not ruled out developing additional preclinical data in cancer models such as breast and head & neck using a combination of radiation and chemotherapy to support pending international divisional patents. Having international patents positions BioCurity as a global leader in drug development using cerium oxide nanoparticles to mitigate radiation side effects," said Dr. Cheryl Baker, PhD. Scientific Co-Founder of BioCurity.


Short and long-term side effects from radiation therapy can impair a cancer patient’s medical treatment plan and can leave cancer survivors with permanent adverse conditions. “There is an estimated 3-billion-dollar healthcare cost for in-patient treatment of medical side effects from radiation therapy in the US annually. The unmet need is well documented,” said Dr. Baker, PhD. The global cancer supportive care market is poised to reach approximately 22 billion dollars by 2026.


*Russia claims cover pancreatic cancer. Japan claims cover lung, breast, pancreas, head & neck, colon, prostate, liver, skin, brain, bone, kidney, ovarian, and uterine cancers.


About BioCurity Pharmaceuticals Inc. 

BioCurity's proprietary technology is designed to protect normal cells from radiation damage without impacting the effectiveness of radiation treatment. Globally, approximately 6 million of the 18 million annually diagnosed new cancer patients receive radiation. The lack of a drug to protect cancer patients' internal tissues and skin from the short and long-term side effects of radiation therapy is a global unmet patient need. Invest in BioCurity through its Regulation Crowdfunding Campaign to support its drug development.  Visit BioCurity's website and follow them on LinkedIn and Facebook.


This news release contains forward-looking statements, including those relating to the product development of BioCurity Pharmaceuticals Inc. (the "Company" or "BioCurity"), clinical and regulatory timelines, market opportunity and other statements that are predictive in nature, or that depend upon or refer to future events or conditions. Forward-looking statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors, including the potential impact of the recent COVID-19 pandemic and the potential impact of sustained social distancing efforts, on our operations, clinical development plans and timelines, which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this news release. BioCurity's lead product candidate is in preclinical development and is not for sale or use. This news release is not an offer to buy any securities of the Company.

Notice of Funds Disbursement

7 months ago

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, BioCurity Pharmaceuticals Inc. has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in BioCurity Pharmaceuticals Inc. be on the lookout for an email that describes more about the disbursement process.


This campaign will continue to accept investments until its indicated closing date.


Thanks for funding the future.

-StartEngine

Notice of Funds Disbursement

7 months ago

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, BioCurity Pharmaceuticals Inc. has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in BioCurity Pharmaceuticals Inc. be on the lookout for an email that describes more about the disbursement process.


This campaign will continue to accept investments until its indicated closing date.


Thanks for funding the future.

-StartEngine

Notice of Funds Disbursement

8 months ago

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, BioCurity Pharmaceuticals Inc. has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in BioCurity Pharmaceuticals Inc. be on the lookout for an email that describes more about the disbursement process.


This campaign will continue to accept investments until its indicated closing date.


Thanks for funding the future.

-StartEngine

Show More Updates End of Updates

Comments ({{profileCtrl.startup.comments_count}} total)

{{profileCtrl.newComment.body.length}}/2500
Please sign in to post a comment.
{{ profileCtrl.commentsLoading ? 'Loading...' : 'Show More Comments' }}